Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AIPAC-003 (Active Immunotherapy and PAClitaxel): A Randomized, Double-blind, Placebo-controlled Phase 3 Trial Testing Eftilagimod Alpha (Soluble LAG-3) in HER2-neg/Low Metastatic Breast Cancer Patients Receiving Paclitaxel, Following an Open-label Dose Optimization

Next Previous
Search
Trial Profile

AIPAC-003 (Active Immunotherapy and PAClitaxel): A Randomized, Double-blind, Placebo-controlled Phase 3 Trial Testing Eftilagimod Alpha (Soluble LAG-3) in HER2-neg/Low Metastatic Breast Cancer Patients Receiving Paclitaxel, Following an Open-label Dose Optimization

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eftilagimod alpha (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; HER2 negative breast cancer; Triple negative breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms AIPAC-003
  • Sponsors Immutep Limited

    • Most Recent Events

    • 31 Jan 2025 According to an Immutep Limited media release,Patients across 22 clinical sites in Europe and the United States have been randomised 1:1 to receive either 30mg or 90mg dosing of efti in combination with paclitaxel to determine the optimal biological dose consistent with the FDA Project Optimus initiative and prior regulatory interaction with FDA. Data cleaning and analysis is ongoing.
    • 03 Oct 2024 Status changed from recruiting to active, no longer recruiting, according to an Immutep Limited media release.
    • 05 Jun 2024 According to an Immutep Limited media release, company announces intention of submit marketing authorisation application to US FDA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top